Sign Up for a Free Account
  • Updated 07.26.2021
  • Released 10.06.1999
  • Expires For CME 07.26.2024

Oxcarbazepine

Introduction

Historical note and terminology

Oxcarbazepine is a homologue of the well-known antiepileptic drug carbamazepine. It was developed as an alternative to carbamazepine for patients who had adverse reaction to carbamazepine or diphenylhydantoin. Despite its structural similarities, oxcarbazepine differs from carbamazepine in pharmacokinetic behavior, biotransformation profile, and interaction potential. Oxcarbazepine is like carbamazepine in its mechanisms of action and antiepileptic efficacy but has better tolerability and fewer interactions with other drugs. Most of the clinical development took place during the early 1990s, when it received approval in several countries. It was approved by the FDA in 1999. In 2003, the FDA approved oxcarbazepine as a monotherapy in children 4 years or older with partial epilepsy. This was the first epilepsy medication in 25 years to be approved for use as monotherapy in children.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com